Annotation
Targeted radiotherapy for neuroblastoma
| The first 150 words of the full text of this article appear below. |
| |
Background |
|---|
Biologically targeted radiotherapy is an established treatment for
thyrotoxicosis and thyroid cancer.1 The principle is to
take advantage of the ability of the thyroid and, to a lesser degree,
differentiated thyroid carcinoma to concentrate and retain iodide. In
this situation the radionuclide (131I) in ionic form is a
natural substrate for targeting thyroid tissue, thus acting both as the
vector, or `missile', and the `warhead'. The success of this form
of radiotherapy in metastatic papillary and follicular thyroid
carcinoma2 is due to the specificity of targeting and the
resulting concentration and retention of 131I in cells of
thyroid origin, after the ablation of residual normal thyroid tissue,
being sufficient to result in tumour eradication. Unfortunately the
thyroid is unique and targeted radioiodine treatment for other tumours
requires specific vectors to carry the `warhead'.With the development
of monoclonal antibodies in 19753 it was hoped that
Erlich's concept of an immunological
This article has been cited by other articles:
-
Oyen, W. J. G., Bodei, L., Giammarile, F., Maecke, H. R., Tennvall, J., Luster, M., Brans, B.
(2007). Targeted therapy in nuclear medicine current status and future prospects. Ann Oncol
18: 1782-1792
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



